Neoadjuvant chemotherapy for breast cancer: Any progress?

The Lancet Oncology

Volumn 15, Issue 2, 2014, Pages 131-132

  Colleoni, Marco ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; GEMCITABINE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG EFFICACY; HUMAN; INFLAMMATORY BREAST CANCER; LETTER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOADJUVANT THERAPY;

EID: 84892984103     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70584-9     Document Type: Letter

References (9)

1. Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012, 19:1508-1516.
2. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24:2206-2223.
3. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012, 30:1796-1804.
4. Prowell TM, Pazdur R Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012, 366:2438-2441.
5. Earl HM, Vallier A-L, Hiller L, et al. Neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel, with or without gemcitabine, for women with high-risk early breast cancer (Neo-tAnGo): an open-label, factorial, randomised phase 3 trial. Lancet Oncol 2013, for the Neo-tAnGo Investigators, pubilshed online Dec 19. http://dx.doi.org/10.1016/S1470-2045(13)70554-0.
6. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012, 366:310-320.
7. Poole CJ, Hiller L, Howard HC, et al. tAnGo: a randomised phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early stage breast cancer (EBC). Proc Am Soc Clin Oncol 2008, 26. abstr 506.
8. Buzdar A, Suman V, Meric-Bernstam F, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 2013, 14:1317-1325.
9. Wildiers H, Forceville K, Paridaens R, et al. Taxanes and anthracyclines in early breast cancer: which first?. Lancet Oncol 2010, 11:219-220.